# Prostate Cancer With OligometaSTatic Relapse: Combining Stereotactic Ablative Radiotherapy and Durvalumab (MEDI4736)

> **NCT03795207** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Institut Cancerologie de l'Ouest** · enrollment: 96 (actual)

## Conditions studied

- Node; Prostate
- Bone Metastases
- Prostate Cancer Patients

## Interventions

- **COMBINATION_PRODUCT:** SBRT + Durvalumab
- **RADIATION:** SBRT

## Key facts

- **NCT ID:** NCT03795207
- **Lead sponsor:** Institut Cancerologie de l'Ouest
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-03-21
- **Primary completion:** 2023-12-27
- **Final completion:** 2027-12-27
- **Target enrollment:** 96 (ACTUAL)
- **Last updated:** 2026-03-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03795207

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03795207, "Prostate Cancer With OligometaSTatic Relapse: Combining Stereotactic Ablative Radiotherapy and Durvalumab (MEDI4736)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03795207. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*